LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

Search

Biogen Inc

Avatud

Sektor Tervishoid

173.67 0.03

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

169.84

Max

174.73

Põhinäitajad

By Trading Economics

Sissetulek

-195M

389M

Müük

2.5B

P/E

Sektori keskmine

28.98

104.138

Aktsiakasum

4.08

Kasumimarginaal

15.729

Töötajad

7,570

EBITDA

-157M

762M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+45.88 upside

Turustatistika

By TradingEconomics

Turukapital

-128M

25B

Eelmine avamishind

173.64

Eelmine sulgemishind

173.67

Uudiste sentiment

By Acuity

49%

51%

165 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Biogen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. sept 2024, 11:00 UTC

Peamised uudised

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29. mai 2024, 15:56 UTC

Tulu
Omandamised, ülevõtmised, äriostud

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

45.88% tõus

12 kuu keskmine prognoos

Keskmine 253.52 USD  45.88%

Kõrge 315 USD

Madal 180 USD

Põhineb 23 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

23 ratings

15

Osta

8

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 185.9Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

165 / 390 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.